{"filing":{"accession_number":"0001171843-26-005316","cik":"0000744218","ticker":"CLDX","company_name":"Celldex Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"f8k_080626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/f8k_080626.htm"},"events":[{"id":25476,"run_id":23127,"accession_number":"0001171843-26-005316","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Celldex issued a press release on August 6, 2026 announcing its financial results for the second quarter of 2026, including consolidated statements of operations and balance sheet data. The disclosure includes quarterly revenues ($22K), operating expenses ($80.6M), net loss ($73.5M), and loss per share ($0.94), along with cash position ($717.6M) and forward-looking guidance that cash is sufficient through 2028. This is a standard earnings release disclosure under Item 2.02.","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26315,"accession_number":"0001171843-26-005316","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Celldex issued a press release on August 6, 2026 announcing its financial results for the second quarter of 2026, including consolidated statements of operations and balance sheet data. The disclosure includes quarterly revenues ($22K), operating expenses ($80.6M), net loss ($73.5M), and loss per share ($0.94), along with cash position ($717.6M) and forward-looking guidance that cash is sufficient through 2028. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:47:57.877743+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26315,"accession_number":"0001171843-26-005316","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Celldex issued a press release on August 6, 2026 announcing its financial results for the second quarter of 2026, including consolidated statements of operations and balance sheet data. The disclosure includes quarterly revenues ($22K), operating expenses ($80.6M), net loss ($73.5M), and loss per share ($0.94), along with cash position ($717.6M) and forward-looking guidance that cash is sufficient through 2028. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:47:57.877743+00:00","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-08-06"}]}